Esperion says cholesterol drug gets U.S. approval; eyes $10 per pill pricing
Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterollowering drug making it the first nonstatin treatment to be cleared for sale in the country in nearly 20 years.
View ArticleFDA Approves Nexletol bempedoic acid to Lower LDLCholesterol
ANN ARBOR Mich. Feb. 21 2020 GLOBE NEWSWIRE Esperion NASDAQESPR announced today that the U.S. Food and Drug Administration FDA approved Nexletol™ bempedoic acid tablet an oral oncedaily...
View ArticleCholesterol Drug That Works Differently Than Widely Prescribed Statin Pills...
Esperions drug called Nexletol lowers lowdensity lipoprotein colloquially known as "bad cholesterol" by 17 over the course of 12 weeks of treatment. This is a nice alternative to statins but those...
View ArticleFDA approves Esperions nonstatin cholesterollowering drug
The drug Nexletol is designed for use with maximally tolerated statins for lowering LDL cholester
View ArticleFDA greenlights first oral daily nonstatin therapy for lowering LDLCholesterol
Esperions ATP Citrase Lyase ACL inhibitor Nexletol bempedoic acid has secured approval from the FDA it has emerged. It is the first oral daily nonstatin LDLCholesterol LDLC lowering therapy approved in...
View ArticleFDA greenlights first oral daily nonstatin therapy for lowering...
FDA greenlights first oral daily nonstatin therapy for lowering LDLCholesterol httpbit.ly390K4WK pharma pic.twitter.comkFhDsZmx6o
View ArticleAn Expert Explains the Latest GoodYes GoodNews About Lung Cancer
By Jennifer Rainey MarquezSOURCE Johnson & JohnsonSUMMARYA new report from the American Cancer Society sheds light on declining death rates from cancerespecially lung cancer. We asked an expert...
View ArticleEsperion's Nexlizet gains FDA clearance as first nonstatin...
Esperion's Nexlizet gains FDA clearance as first nonstatin cholesterollowering combination medicine httpswww.firstwordpharma.comnode1703964 $ESPR
View ArticleFDA approves Esperions nonstatin LDLC lowering drug
Esperion has announced the US Food and Drug Administration FDA has approved Nexlizet bempedoic acid and ezetimibe a nonstatin LDLCholesterol...Read More...The post FDA approves Esperions nonstatin LDLC...
View ArticleFresh off its first FDA approval Esperion gets green light for second...
The FDA approved Nexlizet according to an entry in its database of approved drugs. The new drug combines the active ingredient of Nexletol &8211; which the
View ArticleAre We Doing Enough To Protect Our Hearts Millions Of Patients Face Continued...
1 In 3 Deaths In The Us Are Due To Cardiovascular CV Disease And 45 Of The Us Population Is Estimated To Have CV Disease By 2035. In honor of Heart Health month Dr. John Osborne partnered with D S...
View ArticleStatin Use May Reduce Mortality in HighRisk Prostate Cancer
FRIDAY Feb. 28 2020 Statin use alone or in combination with metformin is associated with lower allcause and prostate cancer PCa mortality among highrisk patients according to a study published online...
View ArticleFDA Approves Nexlizet bempedoic acid and ezetimibe to Lower LDLCholesterol
ANN ARBOR Mich. Feb. 26 2020 GLOBE NEWSWIRE Esperion NASDAQESPR today announced that the U.S. Food and Drug Administration FDA approved Nexlizet bempedoic acid and ezetimibe tablet an oral oncedaily...
View ArticleMonthly News Roundup February 2020
Nexletol Approved as a Firstin Class NonStatin Tablet to Lower LDLCholesterolThe U.S. Food and Drug Administration FDA has approved bempedoic acid Nexletol Esperion an oral oncedaily nonstatin LDLC...
View ArticleBaron & Budd Moves Forward with False Claims Act Case Against AstraZeneca LP
A federal judge in Delaware has decided to allow a False Claims Act suit to proceed against the major pharmaceutical company AstraZeneca LPThe nationally recognized attorneys from Baron & Budd...
View ArticleCardiovascular Safety Signal for Descovy in HIV PrEP
Final DISCOVER data might provide some answers on the higher rate of statin use in patients on Descovy but a growing number of experts are urging clinicians to stick with Truvada. Medscape Medical News
View ArticleUptick in Statin Use After Descovy in HIV PrEP
Final DISCOVER data might provide some answers on the higher rate of statin use in patients on Descovy but a growing number of experts are urging clinicians to stick with Truvada. Medscape Medical News
View ArticleStatins starve cancer cells to death
Johns Hopkins Medicine More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels. Now in experiments with human cells in the laboratory researchers at Johns Hopkins...
View ArticleResearchers uncover clues to how statins kill cancer cells
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels. Now in experiments with human cells in the laboratory researchers at Johns Hopkins Medicine have added to...
View ArticleStatins During Cancer Tx Linked to Fewer Later Heart Failure Events
>MedPage Today Anthracycline and trastuzumab therapy did not seem so cardiotoxic in women with breast cancer who were on statins according to a retrospective cohort study.With a rate of about 4...
View ArticleBempedoic Acid NexletolBempedoic Acid and Ezetimibe Nexlizet
Bempedoic acid and bempedoic acidezetimibe should be prescribed as a supplement to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia or established...
View ArticleACC Statins Cut Heart Failure Risk in Early Breast Cancer Treatment
THURSDAY March 26 2020 For women with early breast cancer receiving anthracyclines or trastuzumab statin treatment is associated with a reduced risk for heart failure hospital visits according to a...
View ArticleBenefits of bempedoic acid in hypercholesterolaemia further demonstrated by...
Bempedoic acid is being developed as a firstinclass affordable oral treatment which lowers lowdensity lipoprotein cholesterol LDLC and which can be combined with other oral treatments to help lower...
View ArticleBRILINTA reduced bleeding vs dual therapy in highrisk coronary patients in...
BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary interventionConsistent results were also...
View ArticleNew firstinclass cholesterollowering treatment NILEMDOÂ and its combination...
NILEMDOÂ bempedoic acid a new firstinclass oral treatment and NUSTENDIÂ bempedoic acid ezetimibe receive approval from the European CommissionESCEAS Guidelines recommend to intensively lower lowdensity...
View Article